New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:38 EDTCPXXCelator announces data, recommendation to continue CPX-351 Phase 3 study
Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
08:18 EDTCPXXCelator Pharmaceuticals presents positive data for its CPX-351 candidate
Celator Pharmaceuticals presented data for CPX-351, its lead product candidate, describing the effects of combining CPX-351 with traditional chemotherapy and novel molecularly targeted agents intended for use in treating AML and other blood cancers. In both cases, the combined agents complemented each other's anti-leukemic properties, resulting in an enhanced overall effect. Chk1 inhibitors and CPX-351 synergized to induce increased DNA fragmentation and apoptosis, leading to increased leukemia cell kill in a number of AML lines as well as in AML patient blasts.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use